Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
Recruiting now · Not applicable
Conditions studied: Oral Mucositis, Quality of Life, Mucositis, Pain, Speech, Saliva, Radiation Toxicity, Chemotherapeutic Toxicity, Head and Neck Cancer
In brief
The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid; (Z)-hexadec-9-enoic acid; (Z)-octadec-9-enoic acid) delivered as a gel and a mouthwash is to be studied in regard to its effect on the incidence of severe oral mucositis in Head \& Neck cancer radiated patients. Patient reported outcome measures seem to be an effective tool to obtain a greater knowledge of the physical and emotional state of patients, being used in this study to assess quality of life of Head \& Neck cancer radiated patients.
Key facts
- Study ID
- NCT05635929
- Run by
- Mucosa Innovations, S.L.
- People needed
- 63
- Starts
- 2022-10-11
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2026-04-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Acute Phase
- Patients diagnosed with Head \& Neck cancer who will undergo radiotherapy (with or without concomitant chemotherapy)
- Patients who are able to read, understand, and complete the questionnaire.
- Patients over 18 years of age.
- Chronic Phase
- Patients who have completed radiotherapy treatment at least 6 months before study enrollement.
- Patients who are able to read, understand, and complete the questionnaire.
- Patients over 18 years of age.
You may not qualify if…
- Acute Phase
- Patients who are unable to properly use the products.
- Patients who do not consent to participate in the study.
- Patients who were being treated for another type of cancer.
- Chronic Phase
- Patients using medications such as pilocarpine, cevimeline, etc., to treat xerostomia.
- Patients who do not consent to participate in the study.
Where it is running
- Mucosa Innovations S.L. — Madrid, Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.